Cargando…
Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss
IL-20 is a proinflammatory cytokine of the IL-10 family that is involved in psoriasis, rheumatoid arthritis, atherosclerosis, and stroke. However, little is known about the role of IL-20 in bone destruction. We explored the function of IL-20 in osteoclastogenesis and the therapeutic potential of ant...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171097/ https://www.ncbi.nlm.nih.gov/pubmed/21844205 http://dx.doi.org/10.1084/jem.20102234 |
_version_ | 1782211714767388672 |
---|---|
author | Hsu, Yu-Hsiang Chen, Wei-Yu Chan, Chien-Hui Wu, Chih-Hsing Sun, Zih-Jie Chang, Ming-Shi |
author_facet | Hsu, Yu-Hsiang Chen, Wei-Yu Chan, Chien-Hui Wu, Chih-Hsing Sun, Zih-Jie Chang, Ming-Shi |
author_sort | Hsu, Yu-Hsiang |
collection | PubMed |
description | IL-20 is a proinflammatory cytokine of the IL-10 family that is involved in psoriasis, rheumatoid arthritis, atherosclerosis, and stroke. However, little is known about the role of IL-20 in bone destruction. We explored the function of IL-20 in osteoclastogenesis and the therapeutic potential of anti–IL-20 monoclonal antibody 7E for treating osteoporosis. Higher serum IL-20 levels were detected in patients with osteopenia and osteoporosis and in ovariectomized (OVX) mice. IL-20 mediates osteoclastogenesis by up-regulating the receptor activator of NF-κB (RANK) expression in osteoclast precursor cells and RANK ligand (RANKL) in osteoblasts. 7E treatment completely inhibited osteoclast differentiation induced by macrophage colony-stimulating factor (M-CSF) and RANKL in vitro and protected mice from OVX-induced bone loss in vivo. Furthermore, IL-20R1–deficient mice had significantly higher bone mineral density (BMD) than did wild-type controls. IL-20R1 deficiency also abolished IL-20–induced osteoclastogenesis and increased BMD in OVX mice. We have identified a pivotal role of IL-20 in osteoclast differentiation, and we conclude that anti–IL-20 monoclonal antibody is a potential therapeutic for protecting against osteoporotic bone loss. |
format | Online Article Text |
id | pubmed-3171097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-31710972012-02-29 Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss Hsu, Yu-Hsiang Chen, Wei-Yu Chan, Chien-Hui Wu, Chih-Hsing Sun, Zih-Jie Chang, Ming-Shi J Exp Med Article IL-20 is a proinflammatory cytokine of the IL-10 family that is involved in psoriasis, rheumatoid arthritis, atherosclerosis, and stroke. However, little is known about the role of IL-20 in bone destruction. We explored the function of IL-20 in osteoclastogenesis and the therapeutic potential of anti–IL-20 monoclonal antibody 7E for treating osteoporosis. Higher serum IL-20 levels were detected in patients with osteopenia and osteoporosis and in ovariectomized (OVX) mice. IL-20 mediates osteoclastogenesis by up-regulating the receptor activator of NF-κB (RANK) expression in osteoclast precursor cells and RANK ligand (RANKL) in osteoblasts. 7E treatment completely inhibited osteoclast differentiation induced by macrophage colony-stimulating factor (M-CSF) and RANKL in vitro and protected mice from OVX-induced bone loss in vivo. Furthermore, IL-20R1–deficient mice had significantly higher bone mineral density (BMD) than did wild-type controls. IL-20R1 deficiency also abolished IL-20–induced osteoclastogenesis and increased BMD in OVX mice. We have identified a pivotal role of IL-20 in osteoclast differentiation, and we conclude that anti–IL-20 monoclonal antibody is a potential therapeutic for protecting against osteoporotic bone loss. The Rockefeller University Press 2011-08-29 /pmc/articles/PMC3171097/ /pubmed/21844205 http://dx.doi.org/10.1084/jem.20102234 Text en © 2011 Hsu et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). |
spellingShingle | Article Hsu, Yu-Hsiang Chen, Wei-Yu Chan, Chien-Hui Wu, Chih-Hsing Sun, Zih-Jie Chang, Ming-Shi Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss |
title | Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss |
title_full | Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss |
title_fullStr | Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss |
title_full_unstemmed | Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss |
title_short | Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss |
title_sort | anti–il-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171097/ https://www.ncbi.nlm.nih.gov/pubmed/21844205 http://dx.doi.org/10.1084/jem.20102234 |
work_keys_str_mv | AT hsuyuhsiang antiil20monoclonalantibodyinhibitsthedifferentiationofosteoclastsandprotectsagainstosteoporoticboneloss AT chenweiyu antiil20monoclonalantibodyinhibitsthedifferentiationofosteoclastsandprotectsagainstosteoporoticboneloss AT chanchienhui antiil20monoclonalantibodyinhibitsthedifferentiationofosteoclastsandprotectsagainstosteoporoticboneloss AT wuchihhsing antiil20monoclonalantibodyinhibitsthedifferentiationofosteoclastsandprotectsagainstosteoporoticboneloss AT sunzihjie antiil20monoclonalantibodyinhibitsthedifferentiationofosteoclastsandprotectsagainstosteoporoticboneloss AT changmingshi antiil20monoclonalantibodyinhibitsthedifferentiationofosteoclastsandprotectsagainstosteoporoticboneloss |